Hu Hang, Xu Defeng, Xu Qingbo, Tang Yuxiang, Hong Jun, Hu Yu, Wang Jianhao, Ni Xinye
Second People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu, China.
School of Pharmacy, Changzhou University, Changzhou, Jiangsu, China.
Mater Today Bio. 2023 Jan 4;18:100542. doi: 10.1016/j.mtbio.2023.100542. eCollection 2023 Feb.
Chemo-photodynamic therapy shows great potential for cancer treatment. However, the rational integration of chemotherapeutic agents and photosensitizers to construct an intelligent nanoplatform with synergistic therapeutic effect is still a great challenge. In this work, curcumin-loaded reduction-responsive prodrug nanoparticles of new indocyanine green (Cur@IR820-ss-PEG) were developed for synergistic cancer chemo-photodynamic therapy. Cur@IR820-ss-PEG exhibit high drug loading content and special worm-like morphology, contributing to their efficient cellular uptake. Due to the presence of the disulfide bond between IR820 and PEG, Cur@IR820-ss-PEG display reduction responsive drug release behaviors. The efficient cellular uptake and reduction triggered drug release of Cur@IR820-ss-PEG lead to their enhanced in vitro cytotoxicity against 4T1cells as compared to the mixture of IR820 and curcumin (IR820/Cur) under laser irradiation. Besides, Cur@IR820-ss-PEG exhibit prolonged blood half-life time, better tumor accumulation and retention, enhanced tumor hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial cell growth factor (VEGF) suppression effect as compared to IR820/Cur. In vivo antitumor activity study, Cur@IR820-ss-PEG effectively inhibit the tumor angiogenesis, which potentiates the PDT efficacy and leads to the best in vivo antitumor effect of Cur@IR820-ss-PEG. This work provides a novel and relatively simple strategy for synergistic cancer chemo-photodynamic therapy.
化学光动力疗法在癌症治疗中显示出巨大潜力。然而,将化疗药物和光敏剂合理整合以构建具有协同治疗效果的智能纳米平台仍然是一个巨大挑战。在这项工作中,开发了用于协同癌症化学光动力疗法的负载姜黄素的新型吲哚菁绿还原响应前药纳米颗粒(Cur@IR820-ss-PEG)。Cur@IR820-ss-PEG表现出高载药量和特殊的蠕虫状形态,有助于其高效的细胞摄取。由于IR820和PEG之间存在二硫键,Cur@IR820-ss-PEG表现出还原响应性药物释放行为。与激光照射下IR820和姜黄素的混合物(IR820/Cur)相比,Cur@IR820-ss-PEG的高效细胞摄取和还原触发的药物释放导致其对4T1细胞的体外细胞毒性增强。此外,与IR820/Cur相比,Cur@IR820-ss-PEG表现出更长的血液半衰期、更好的肿瘤蓄积和滞留、增强的肿瘤缺氧诱导因子-1α(HIF-1α)和血管内皮细胞生长因子(VEGF)抑制作用。在体内抗肿瘤活性研究中,Cur@IR820-ss-PEG有效抑制肿瘤血管生成,这增强了光动力疗法的疗效,并导致Cur@IR820-ss-PEG最佳的体内抗肿瘤效果。这项工作为协同癌症化学光动力疗法提供了一种新颖且相对简单的策略。